No abstract available
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Clinical Trials as Topic
-
Drug Resistance, Neoplasm*
-
Gene Expression Regulation, Enzymologic
-
Gene Expression Regulation, Neoplastic
-
Genes, ras / drug effects
-
Humans
-
Indoles / pharmacology*
-
MAP Kinase Kinase Kinases / metabolism
-
Melanoma / drug therapy*
-
Melanoma / secondary
-
Mutation*
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins B-raf / genetics
-
Proto-Oncogene Proteins B-raf / metabolism*
-
Proto-Oncogene Proteins c-raf / metabolism
-
Receptors, Platelet-Derived Growth Factor / metabolism
-
Signal Transduction / drug effects
-
Sulfonamides / pharmacology*
-
Time Factors
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Indoles
-
Proto-Oncogene Proteins
-
Sulfonamides
-
Vemurafenib
-
Receptors, Platelet-Derived Growth Factor
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Proto-Oncogene Proteins c-raf
-
MAP Kinase Kinase Kinases
-
MAP3K8 protein, human